Table 3.
Summary of the performance of DectiSomes, relative to untargeted control drug loaded liposomes
| A. In vitro assays | |||
|---|---|---|---|
| DectiSomes (References) | Pathogen | Increases liposome bindingb | Increases in vitro killing / inhibitionb |
| DEC1-AmB-LLs [107] [217] | Aspergillus fumigatus | >200-fold | >50-fold |
| Rhizopus delemar | >1,900-fold hyphae >120-fold germlings |
>70-fold | |
| Candida albicans | >130-fold | No data | |
| Cryptococcus neoformans | Yes, but not quatified | No data | |
| DEC1-AmBisomef [218] | C. albicans | >90-fold | No data |
| DEC2-AmB-LLs [220] | A. fumigatus | >50-fold | >30-fold |
| C. albicans | >100-fold | >90-fold | |
| C. neoformans | >150-fold | >10-fold | |
| DEC2-AmBisomef [218] | C. albicans | >25-fold | No data |
| DEC3-AmB-LLs [216] | C. albicans | yes | yes |
| R. delemar | yes | yes | |
| C. neoformans | yes | marginal | |
| DCS12-AmB-LLs (DC-SIGN isoform) [215] | A. fumigatus | >25-fold | >70-fold |
| C. albicans | >25-fold | >50-fold | |
| C. neoformans | >30-fold | >10-fold | |
| B. In vivo assays in murine models of invasive fungal diseases | |||
|---|---|---|---|
| Liposome, antifungal, mouse model (Reference) | Increase in liposome binding in effected organ | Reduction in fungal burden in effected organ | Increase in percent of surviving miced |
|
DEC1-AmB-LLs 0.2 mg/kg AmB |
|||
| Systemic candidiasis neutropenic model [218] | 24-fold in kidneysb | 6-fold in the kidneysb | 18% to 44% |
|
DEC2-AmB-LLs 0.2 mg/kg AmB |
|||
| Pulmonary aspergillosis neutropenic model [219] | 30-fold in lungsb | 40-fold in the lungsb | 0% to 58% |
| Pulmonary aspergillosis steroid model [219] | aN.D. | 20-fold in the lungsb | aN.D. |
| Systemic Candidiasis neutropenic model [218] | 50-fold kidneys | 12-fold kidneys | 8% to 58% |
|
DEC2-AFG-LLse 0.6 mg/kg AFG |
|||
| Systemic Candidiasis neutropenic model [218] | 9.8-fold kidneys | ||
|
DEC2-AmBisomef 0.2 mg/kg AmB |
|||
| Systemic Candidiasis neutropenic model [218] | 6.1-fold kidneys | ||